Navigation Links
Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
Date:3/6/2008

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, March 6 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has started its first EDACS(TM) product Phase I clinical trial. EDACS(TM) is Akela's patent pending platform technology to prevent abuse of controlled substances.

This Phase I trial for the first EDACS(TM) based product is an open-label, randomized, single-dose, cross-over study investigating the pharmacokinetics and safety of 3 different extended release formulations of a well-known opioid product compared to the same opioid drug immediate release formulation. The study will be carried out in 12 healthy subjects, and the results are expected to be available in Q3/2008.

"The abuse of prescription drugs is approaching epidemic proportions in numerous countries. The costs to society associated with this abuse are tremendous. Akela has developed a platform technology to prevent the abuse of such substances by preventing the tampering of extended release dosage forms as well as unintentional dose dumping in alcohol. " said Dr. Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc. "We believe that our platform technology is perfectly suited to meet the increasing market demand as well as regulatory pressure for abuse deterrent formulations."

About EDACS(TM):

EDACS(TM) is a patent pending platform technology which utilizes extrusion technology to prepare an insoluble matrix containing dispersed drug which can be shaped into tablets. The matrix is water insoluble, slightly soluble in ethanol, not friable, does not break on compression or allow for crushing and inhalation and does not allow for dissolution and injection.

About Akela Pharma Inc.:

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Akela Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE Akela Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
2. Akela Pharma provides corporate update
3. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
4. Akela Pharma reports results for third quarter of fiscal 2007
5. AKELA Pharma Inc. announces U.S. public offering and proposed listing
6. Akela Pharma Inc. Completes Share Consolidation
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. MinuteClinic Hits 500th Clinic Mark; New Locations Open in Dallas, Los Angeles and Orlando CVS/pharmacy Stores
9. Notice of Bradmer Pharmaceuticals Conference Call
10. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
11. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular ... Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign on ... muscular dystrophy, ALS and related diseases that severely limit strength and mobility. ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
(Date:2/5/2016)... Seattle, WA (PRWEB) , ... February 05, 2016 ... ... consulting firm, ranked #3 in the 2015 Best in KLAS: Software & Services ... The annual Best in KLAS report independently ranks vendor performance by healthcare ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... of CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, ... offers a complete range of oral health care, including general dentistry, cosmetic treatments, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Ind. , Feb. 5, 2016  Zimmer Biomet ... pricing of the previously announced underwritten secondary offering of ... its stockholders, consisting of affiliates of Blackstone and Goldman ... at an initial price of $96.45 per share. The ... the offering.  Neither Zimmer Biomet nor any of its ...
(Date:2/5/2016)... Site Profile: --> ... Recognition People, announced their latest primary healthcare case study where speech ... times and to save the practice money. Site Profile: ... Challenge: --> ,- Wirral CCG ,- VoicePower client ... ,- Wirral CCG ,- VoicePower client since 2013 Challenge: ...
(Date:2/4/2016)... , Feb. 4, 2016 For hospitals ... or those already participating in the program, the Health ... referred to as the , Mega-Guidance , could have ... guidance is published in September 2016. Essential ... and Service Marketing , summarizes the Mega-Guidance,s key proposed ...
Breaking Medicine Technology: